Microbial Genomics as a Catalyst for Targeted Antivirulence Therapeutics
Virulence arresting drugs (VAD) are an expanding class of antimicrobial treatment that act to “disarm” rather than kill bacteria. Despite an increasing number of VAD being registered for clinical use, uptake is hampered by the lack of methods that can identify patients who are most likely to benefit...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-04-01
|
Series: | Frontiers in Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2021.641260/full |
id |
doaj-1894861c9fdb460ba099e12a086565e8 |
---|---|
record_format |
Article |
spelling |
doaj-1894861c9fdb460ba099e12a086565e82021-04-13T04:27:52ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2021-04-01810.3389/fmed.2021.641260641260Microbial Genomics as a Catalyst for Targeted Antivirulence TherapeuticsVitali Sintchenko0Vitali Sintchenko1Vitali Sintchenko2Verlaine Timms3Eby Sim4Rebecca Rockett5Rebecca Rockett6Nathan Bachmann7Matthew O'Sullivan8Matthew O'Sullivan9Matthew O'Sullivan10Ben Marais11Ben Marais12Marie Bashir Institute for Infectious Diseases and Biosecurity, The University of Sydney, Sydney, NSW, AustraliaCentre for Infectious Diseases and Microbiology—Public Health, Westmead Hospital, Westmead, NSW, AustraliaCentre for Infectious Diseases and Microbiology Laboratory Services, NSW Health Pathology—Institute of Clinical Pathology and Medical Research, Westmead, NSW, AustraliaCentre for Infectious Diseases and Microbiology—Public Health, Westmead Hospital, Westmead, NSW, AustraliaCentre for Infectious Diseases and Microbiology Laboratory Services, NSW Health Pathology—Institute of Clinical Pathology and Medical Research, Westmead, NSW, AustraliaMarie Bashir Institute for Infectious Diseases and Biosecurity, The University of Sydney, Sydney, NSW, AustraliaCentre for Infectious Diseases and Microbiology—Public Health, Westmead Hospital, Westmead, NSW, AustraliaCentre for Infectious Diseases and Microbiology—Public Health, Westmead Hospital, Westmead, NSW, AustraliaMarie Bashir Institute for Infectious Diseases and Biosecurity, The University of Sydney, Sydney, NSW, AustraliaCentre for Infectious Diseases and Microbiology—Public Health, Westmead Hospital, Westmead, NSW, AustraliaCentre for Infectious Diseases and Microbiology Laboratory Services, NSW Health Pathology—Institute of Clinical Pathology and Medical Research, Westmead, NSW, AustraliaMarie Bashir Institute for Infectious Diseases and Biosecurity, The University of Sydney, Sydney, NSW, AustraliaChildren's Hospital at Westmead, Westmead, NSW, AustraliaVirulence arresting drugs (VAD) are an expanding class of antimicrobial treatment that act to “disarm” rather than kill bacteria. Despite an increasing number of VAD being registered for clinical use, uptake is hampered by the lack of methods that can identify patients who are most likely to benefit from these new agents. The application of pathogen genomics can facilitate the rational utilization of advanced therapeutics for infectious diseases. The development of genomic assessment of VAD targets is essential to support the early stages of VAD diffusion into infectious disease management. Genomic identification and characterization of VAD targets in clinical isolates can augment antimicrobial stewardship and pharmacovigilance. Personalized genomics guided use of VAD will provide crucial policy guidance to regulating agencies, assist hospitals to optimize the use of these expensive medicines and create market opportunities for biotech companies and diagnostic laboratories.https://www.frontiersin.org/articles/10.3389/fmed.2021.641260/fullvirulencegenome sequence analysisantibacterial treatmentsurveillanceantimicrobial stewardship |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Vitali Sintchenko Vitali Sintchenko Vitali Sintchenko Verlaine Timms Eby Sim Rebecca Rockett Rebecca Rockett Nathan Bachmann Matthew O'Sullivan Matthew O'Sullivan Matthew O'Sullivan Ben Marais Ben Marais |
spellingShingle |
Vitali Sintchenko Vitali Sintchenko Vitali Sintchenko Verlaine Timms Eby Sim Rebecca Rockett Rebecca Rockett Nathan Bachmann Matthew O'Sullivan Matthew O'Sullivan Matthew O'Sullivan Ben Marais Ben Marais Microbial Genomics as a Catalyst for Targeted Antivirulence Therapeutics Frontiers in Medicine virulence genome sequence analysis antibacterial treatment surveillance antimicrobial stewardship |
author_facet |
Vitali Sintchenko Vitali Sintchenko Vitali Sintchenko Verlaine Timms Eby Sim Rebecca Rockett Rebecca Rockett Nathan Bachmann Matthew O'Sullivan Matthew O'Sullivan Matthew O'Sullivan Ben Marais Ben Marais |
author_sort |
Vitali Sintchenko |
title |
Microbial Genomics as a Catalyst for Targeted Antivirulence Therapeutics |
title_short |
Microbial Genomics as a Catalyst for Targeted Antivirulence Therapeutics |
title_full |
Microbial Genomics as a Catalyst for Targeted Antivirulence Therapeutics |
title_fullStr |
Microbial Genomics as a Catalyst for Targeted Antivirulence Therapeutics |
title_full_unstemmed |
Microbial Genomics as a Catalyst for Targeted Antivirulence Therapeutics |
title_sort |
microbial genomics as a catalyst for targeted antivirulence therapeutics |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Medicine |
issn |
2296-858X |
publishDate |
2021-04-01 |
description |
Virulence arresting drugs (VAD) are an expanding class of antimicrobial treatment that act to “disarm” rather than kill bacteria. Despite an increasing number of VAD being registered for clinical use, uptake is hampered by the lack of methods that can identify patients who are most likely to benefit from these new agents. The application of pathogen genomics can facilitate the rational utilization of advanced therapeutics for infectious diseases. The development of genomic assessment of VAD targets is essential to support the early stages of VAD diffusion into infectious disease management. Genomic identification and characterization of VAD targets in clinical isolates can augment antimicrobial stewardship and pharmacovigilance. Personalized genomics guided use of VAD will provide crucial policy guidance to regulating agencies, assist hospitals to optimize the use of these expensive medicines and create market opportunities for biotech companies and diagnostic laboratories. |
topic |
virulence genome sequence analysis antibacterial treatment surveillance antimicrobial stewardship |
url |
https://www.frontiersin.org/articles/10.3389/fmed.2021.641260/full |
work_keys_str_mv |
AT vitalisintchenko microbialgenomicsasacatalystfortargetedantivirulencetherapeutics AT vitalisintchenko microbialgenomicsasacatalystfortargetedantivirulencetherapeutics AT vitalisintchenko microbialgenomicsasacatalystfortargetedantivirulencetherapeutics AT verlainetimms microbialgenomicsasacatalystfortargetedantivirulencetherapeutics AT ebysim microbialgenomicsasacatalystfortargetedantivirulencetherapeutics AT rebeccarockett microbialgenomicsasacatalystfortargetedantivirulencetherapeutics AT rebeccarockett microbialgenomicsasacatalystfortargetedantivirulencetherapeutics AT nathanbachmann microbialgenomicsasacatalystfortargetedantivirulencetherapeutics AT matthewosullivan microbialgenomicsasacatalystfortargetedantivirulencetherapeutics AT matthewosullivan microbialgenomicsasacatalystfortargetedantivirulencetherapeutics AT matthewosullivan microbialgenomicsasacatalystfortargetedantivirulencetherapeutics AT benmarais microbialgenomicsasacatalystfortargetedantivirulencetherapeutics AT benmarais microbialgenomicsasacatalystfortargetedantivirulencetherapeutics |
_version_ |
1721529338048806912 |